ESMO 2019 | ALK-positive NSCLC: CNS progression

Sanjay Popat

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, discusses the risk of CNS progression in patients with ALK-positive metastatic Non-Small cell lung cancer (NSCLC), and how we can determine and reduce the risk. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics